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Silymarin (Sy) shows limited water solubility and poor oral bioavailability. Water-soluble
hydroxypropyl (HPBCD) and randomly methylated (RAMEB) β-cyclodextrins were
designed to enhance anti-fibrotic efficiency of silymarin in CCl4-induced liver fibrosis
in mice. Experimental fibrosis was induced by intraperitoneal injection with 2 ml/kg
CCl4 (20% v/v) twice a week, for 7 weeks. Mice were orally treated with 50 mg/kg
of Sy-HPBCD, Sy-RAMEB and free silymarin. For assessment of the spontaneous
reversion of fibrosis, CCl4 treated animals were investigated after 2 weeks of recovery
time. The CCl4 administration increased hepatic oxidative stress, augmented the
expression of transforming growth factor-β1 (TGF-β1) and Smad 2/3, and decreased
Smad 7 expression. Furthermore, increased α-smooth muscle actin (α-SMA) expression
indicated activation of hepatic stellate cells (HSCs), while up-regulation of collagen I
(Col I) and matrix metalloproteinases (MMPs) expression led to an altered extracellular
matrix enriched in collagen, confirmed as well by trichrome staining and electron
microscopy analysis. Treatment with Sy-HPBCD and Sy-RAMEB significantly reduced
liver injury, attenuating oxidative stress, restoring antioxidant balance in the hepatic
tissue, and significantly decreasing collagen deposits in the liver. The levels of pro-
fibrogenic markers’ expression were also significantly down-regulated, whereas in the
group for spontaneous regression of fibrosis, they remained significantly higher, even
at 2 weeks after CCl4 administration was discontinued. The recovery was significantly
lower for free silymarin group compared to silymarin/β cyclodextrins co-treatments. Sy-
HPBCD was found to be the most potent anti-fibrotic complex. We demonstrated that
Sy-HPBCD and Sy-RAMEB complexes decreased extracellular matrix accumulation by
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inhibiting HSC activation and diminished the oxidative damage. This might occur via
the inhibition of TGF-β1/Smad signal transduction and MMP/tissue inhibitor of MMPs
(TIMP) rebalance, by blocking the synthesis of Col I and decreasing collagen deposition.
These results suggest that complexation of silymarin with HPBCD or RAMEB represent
viable options for the its oral delivery, of the flavonoid as a potential therapeutic entity
candidate, with applications in the treatment of liver fibrosis.
Keywords: silymarin, HPBCD, RAMEB, liver fibrosis, ECM, collagen
INTRODUCTION
Hepatic fibrosis is a pathological consequence of chronic liver
diseases and results in excessive scar tissue, due to an incorrect
wound healing response to liver injury. This pathology is
characterized by necrosis and/or apoptosis of parenchymal cells
and their replacement with an altered extracellular matrix (ECM)
enriched in types I and III fibrillar collagens (Mallat and
Lotersztajn, 2013). Accumulation of ECM proteins changes the
liver architecture and ultimately leads to cirrhosis, a condition
defined by an abnormal parenchymal structure, with fibrotic
septa surrounding regenerating nodules (Friedman, 2003) and
pathologic angiogenesis (Bocca et al., 2015). Findings in both
human studies and animal models revealed that development
of liver fibrosis is a dynamic process that can be modulated by
arresting progression and/or promoting resolution (Trautwein
et al., 2015).
Several studies have been conducted to find the main herbal
formulations and plant bioactive molecules designed for liver
fibrosis therapy (Hermenean et al., 2016). Most of the natural
anti-fibrotic compounds, i.e., chrysin (Balta et al., 2015), caffeine
(Wang et al., 2015), morin (Heeba and Mahmoud, 2014;
MadanKumar et al., 2014, 2015), mistletoe alkaloid fractions
(Jiang et al., 2014) or Chinese herbal formula (Lin et al., 2011,
2012), have directly inactivated hepatic stellate cells (HSC),
myofibroblasts and the ECM. Some “indirect antifibrotics”,
such as Amomum xanthoides extract (Wang et al., 2011) and
Terminalia bellerica aerial parts ethyl acetate extract (Rashed
et al., 2014), addressed to other pathways.
Silymarin, a flavonoid complex a mixture of flavonolignans
and taxifolin, is extracted from the seeds of milk thistle (Silybum
marianum L.). The active constituents of silymarin are: silibinin,
isosilybinin, silydianin, and silychristin, of which silibinin is the
major and most active component, representing about 60–70% of
flavonoids (Saller et al., 2001).
Silymarin and silibinin show the ability to protect mammals’
liver against hepatotoxicity induced by ethanol (Zhang et al.,
2013), carbon tetrachloride (Yadav et al., 2008; Salam et al.,
2009; Shaker et al., 2010), cisplatin (Mansour et al., 2006;
Abdel-Rahman and Abdel-Hady, 2013), arsenic (Jain et al.,
2011; Muthumani and Prabu, 2012), anti-tuberculosis drugs
(Eminzade et al., 2008), thioacetamide (Ghosh et al., 2016) and
acetaminophen (Avizeh et al., 2010), as it has been previously
shown. Moreover, silibinin have showed efficacy to alleviate
non-alcoholic fatty liver disease, through nicotinamide adenine
dinucleotide (NAD+) level restoration (Salomone et al., 2017).
One of the major limitations of silymarin is the poor
water solubility and oral-bioavailability. Its oral absorption is
only about 23–47% (Ghosh et al., 2010), generating an oral
bioavailability of 0.73% (Wu et al., 2007). This poor bioavailability
results from the instability in gastric environment (Blumenthal
et al., 2000), poor intestinal absorption (Loguercio and Festi,
2011) and poor water solubility (Blumenthal et al., 2000). This
underlines that very high amount of Sylimarin are needed in
order to achieve biological activities. In this sense, Clichici
et al. (2016) demonstrated that at least 200 mg/kg are necessary
to reduce the extent of the experimental fibrosis to the liver.
However, concerns about the administration of high doses of
silymarin remain, while some results show that it has a toxic dose
of>1.44 g per week (Wu et al., 2011).
Some pharmaceutical formulations, such as nanostructured
lipid carriers (NLCs) (Jia et al., 2010), liposomes (El-Samaligy
et al., 2006; Elmowafy et al., 2013; Kumar et al., 2014),
nanoemulsions (Parveen et al., 2011), solid lipid nanoparticles
(Cengiz et al., 2015), gold nanoparticles (Kabir et al., 2014),
alginate-poly (lactic-co-glycolic acid) nano/micro hydrogel
matrices (El-Sherbiny et al., 2011), self-nanoemulsifying drug
delivery systems (Iosio et al., 2011; Chen et al., 2015), have
been used to increase the aqueous solubility of silymarin.
Among these, gold nanoparticles were designed to ameliorate
liver fibrosis, and Au-silymarin conjugates were administered
for up to 14 weeks without any noticeable side effects in the
morphology of heart, kidney and lungs of the animals (Kabir
et al., 2014).
Cyclodextrins (CDs) are a cyclic oligosaccharides family useful
for drug delivery of poor water-soluble natural compounds in
order to enhance their solubility, bioavailability, and stability
when are orally administered (Suvarna et al., 2017).
In this study, silymarin – hydroxypropyl-β-cyclodextrin (Sy-
HPBCD) and silymarin – randomly methylated-β-cyclodextrin
(Sy-RAMEB) complexes were developed in order to improve
silymarin anti-fibrotic activity at the lowest therapeutical dose,
by increasing their potential solubilization and to prevent
their metabolic degradation within the gastrointestinal tract
after oral administration. To our knowledge, there are no
thorough studies so far, reporting Sy-HPβCD and Sy-RAMEB
anti-fibrotic activity in animal models of liver fibrosis. We
proposed that Sy-HPBCD and/or Sy-RAMEB could attenuate
the progression of liver fibrosis better than silymarin itself, by
reducing oxidative stress and expression of inflammatory and
pro-fibrogenic markers in the progression of CCl4-induced liver
fibrosis.
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MATERIALS AND METHODS
Reagents and Antibodies
All chemicals and solvents used in the study were of analytical
grade.
2-Hydroxypropyl)-beta-cyclodextrin (HPBCD) and methyl-
beta-cyclodextrin (RAMEB) were purchased from Cyclolab
Ltd. (Budapest, Hungary). Silymarin 98% and carboxymethyl
cellulose were purchased from Sigma-Aldrich (Germany). Rabbit
polyclonal TGF-β1 (sc-146), rabbit polyclonal Smad 2/3 (sc-
8332), mouse monoclonal α-SMA (sc-53142), rabbit polyclonal
NF-κB p65 (sc-109) antibodies were supplied from Santa Cruz
Biotechnology (Santa Cruz, CA, United States), rabbit polyclonal
Anti-Col-I antibody (ab34710) from Abcam (United States)
and mouse monoclonal Anti-MMP-1 antibody (NBP2-22123)
from NovusBio (Novus, United States). Novocastra kit for
immunohistochemistry was purchased from Leica Microsystems
(Germany).
Preparation of Silymarin-Cyclodextrin
Physical Mixtures
The required amount of silymarin and cyclodextrins (RAMEB
and HPBCD) were measured out and mixed thoroughly in
mortar without using solvent. The prepared physical mixtures
(PM) were used in solubility and SEM studies.
Preparation of Silymarin-Cyclodextrin
Complexes
Silymarin-cyclodextrin complexes were produced with HPBCD
and RAMEB. Complexes were prepared by kneading method.
Briefly, silymarin was dissolved in 96% ethanol and mixed with
cyclodextrin in a mortar to obtain a mixture with 1:20 silymarin:
cyclodextrin mass ratio (1:6 molar ratio). The mixture was dried
at 30◦C with continuous mixing. After drying the products were
ground and mixed thoroughly again. At first Silymarin was
dissolved in 96% ethanol to obtain a concentrated (8 mg/ml)
Silymarin solution. Cyclodextrins were measured into mortars
and mixed with the required amount of Silymarin solution to
obtain a mixture with 1:20 silymarin: cyclodextrin mass ratio
(1:6 molar ratio). As both RAMEB and HPBCD are soluble
in ethanol cyclodextrins were also dissolved in the ethanolic
Silymarin solution at this step. The ethanol was evaporated
from the solutions at 30◦C with continuous mixing. During
evaporation the solutions containing cyclodextrins and silymarin
were concentrated and viscous pastes were obtained, which were
further kneaded and dried continuously. After perfect drying the
products were ground and mixed thoroughly again.
Phase-Solubility Study
Aliquots of 100 mg silymarin were measured into 12-well plates.
Cyclodextrin solutions were prepared in the concentration range
of 0–76 mM by Milli-Q water. A volume of 2 ml of cyclodextrin
solutions was measured into the wells and mixed with silymarin
powder. The mixtures were shaken for 48 h at 22◦C. After the
incubation, 300 µl supernatant was removed from each samples
and analyzed by High Performance Liquid Chromatography
(HPLC) to determine the concentration of the dissolved
silymarin. Using the concentration data, phase-solubility curves
were plotted for the characterization of silymarin complexation
by cyclodextrins (Higuchi and Connors, 1965; Loftsson et al.,
2005a,b; Jambhekar and Breen, 2016).
The 1:1 molar ratio of silymarin:CD inclusion complexes was
assumed. The stability constants (K1:1) were calculated from the
slope of the phase-solubility diagrams according to the equation:
K1:1 = slope/[S0(1− slope)],
where S0 is the solubility of the silymarin components in the
absence of cyclodextrins.
Complexation efficiencies were calculated from the slope of
the phase-solubility diagrams according to the equation:
CE = S0 · K1:1 = slope/(1− slope).
HPLC Analysis
The samples were analyzed using a HPLC system Merck-
Hitachi ELITE LaCrom consisting of a pump (L-2130), degasser,
automated injector, column oven (L-2300) and a photodiode
array detector (DAD). The column module was kept at 40◦C,
and the DAD was set to collect signals within the spectral range
of 220–400 nm. The separation of silymarin components was
performed on the Zorbax SB C-18 column (4.6 mm × 75 mm,
3.5 µm) (Agilent, Santa Clara, CA, United States). The injected
volume of samples was 100 µl. A gradient elution system (flow
rate of 0.8 ml min−1) was applied. The mobile phase A was
water containing 0.1% (v/v) formic acid, and mobile phase B
was methanol. The gradient condition was the following: at the
beginning 80:20 (v/v) A and B, 0–80 min linear change to 50:50
(v/v) A:B. The analyses were performed with EZChrom Elite
softwareTM (Hitachi, Tokyo, Japan), which was also used for
collecting and processing data.
Scanning Electron Microscopy (SEM)
The morphology of solid particles of cyclodextrin, silymarin,
silymarin-cyclodextrin physical mixtures and silymarin-
cyclodextrin complexes were investigated by Hitachi S-4300 CFE
SEM (Scanning Electron Microscope) using 15 kV accelerating
voltage. The specimens were coated with gold for imaging.
Animals and Experimental Design
Male CD1 mice from our breeding colony, weighting 26 ± 3 g
(5–6 weeks old), were used for this study. The mice were fed with
a standard rodent diet and were maintained at 12 h light/dark
cycle at constant temperature and humidity. All experimental
procedures were approved by the Ethical Committee of the
“Vasile Goldis” Western University of Arad and certified by
the National Sanitary Veterinary and Food Safety Authority of
Romania.
Mice were divided into six groups of 10 (Figure 1). Group 1
(control group) was given orally 0.9% NaCl solution for 7 weeks,
followed by 0.7% carboxymethyl cellulose (CMC) as for 2 weeks.
Group 2 (CCl4 group) received CCl4 in olive oil (20% v/v, 2 ml/kg
b.w.) 2 times a week for 7 weeks and were euthanatized 72 h
Frontiers in Pharmacology | www.frontiersin.org 3 August 2018 | Volume 9 | Article 883
fphar-09-00883 August 9, 2018 Time: 19:1 # 4
Gharbia et al. Silymarin/β-Cyclodextrin’s Enhanced Anti-liver Fibrosis Effect
FIGURE 1 | Schematic diagram of the experimental protocol.
after the last injection for the confirmation of liver fibrosis. Group
3 (CCl4 control group) received CCl4 in olive oil (20% v/v,
2 ml/kg b. w.) 2 times a week for 7 weeks, followed by 2 weeks of
recovery for the fibrosis spontaneous resolution analysis. Group
4 (CCl4/Sy-RAMEB group) was given CCl4 as to groups 2 and
3, followed by 50 mg/kg b.w. Sy-RAMEB orally administration
once a day for 2 weeks more. Group 5 (CCl4/Sy-HPBCD group)
was given CCl4 as to groups 2 and 3, followed by 50 mg/kg b.w.
Sy-HPBCD orally administration once a day for 2 weeks more.
Group 6 (CCl4/Sy group) was given CCl4 as group to 2 and 3,
followed by 50 mg/kg b.w. free silimarin orally administration
once a day for 2 weeks more.
The dose of silymarin was selected based on previous
investigations that used the lowest effective dose for liver fibrosis
alleviation (Mourelle et al., 1989; Boigk et al., 1997).
At the end of the 9-week treatment (1–6 groups, except group
2), mice were euthanatized, liver biopsies were collected for
biochemical, histological and electron microscopy evaluations.
The remaining liver tissues were snap-frozen to extract the total
RNA.
Cell Lysate Preparation
Mice livers (0.1 g of tissue) were mixed with 1 ml of ice-cold
0.1 M TRIS-HCl – 5 mM EDTA buffer (pH 7.4) and homogenized
for 2 min at 30 Hz using a ball mill (type MM 301, Retsch
GmbH & Co, Haan, Germany). The samples were centrifuged at
10000 × g for 10 min at 4◦C to obtain the supernatants which
were further used for the biochemical assays. The protein content
was measured using the Bradford reagent and bovine serum
albumin as standard.
Measurement of Lipid Peroxidation
The content of hepatic malondialdehyde (MDA) was measured in
order to estimate lipid peroxidation. The fluorimetric technique
previously described by Dinischiotu et al. (2013) was based on the
reaction of MDA with thiobarbituric acid. Relative fluorescence
units read at FP-6300 JASCO spectrofluorometer (λex = 520 nm;
λem = 549 nm) were transformed to nmol MDA using 1,1,3,3-
tetramethoxypropane as standard. The values were normalized to
the protein concentration and shown as percentages of control.
Assessment of Reduced Glutathione
(GSH) Level
The cell lysates were deproteinized with 5% sulfosalicylic
acid (Sigma-Aldrich, United States) and the GSH content
was spectrophotometrically measured, using the commercial
glutathione assay kit (Sigma-Aldrich), based on the reduction
of 5,5′-dithiobis-2-nitrobenzoic acid (DTNB) into 5-thio-2-
nitrobenzoic acid (TNB). The absorbance was recorded at 405 nm
Frontiers in Pharmacology | www.frontiersin.org 4 August 2018 | Volume 9 | Article 883
fphar-09-00883 August 9, 2018 Time: 19:1 # 5
Gharbia et al. Silymarin/β-Cyclodextrin’s Enhanced Anti-liver Fibrosis Effect
using the FlexStation 3 multi-mode microplate reader and the
concentration was calculated in nmoles/mg protein, presented as
a percentage of control.
Determination of Advanced Oxidation
Protein Products (AOPP) Concentration
The AOPP concentration was assessed as previously described
(Petrache et al., 2012). A volume of 200 µL protein extract was
incubated with 10 µL of 1.16 M potassium iodide and 20 µL of
glacial acetic acid. The optical densities were read at 340 nm in
a 96-well plate using the FlexStation 3 multi-mode microplate
reader and the AOPP levels were calculated using a chloramine-T
standard curve and reported to the protein concentration.
Measurement of Carbonyl Groups
Content
The concentration of carbonyl groups was assessed as described
in a previous work (Petrache et al., 2012). Briefly, the diluted total
protein extract was incubated with an equal volume of 10 mM
2,4-dinitrophenylhydrazine for 1 h at room temperature, and
after that, 20% TCA was added in a volume equal to previous
solution. The mixture was incubated for 30 min on ice and
centrifuged for 3 min at 13,000 rpm at room temperature in order
to obtain the pellet which was washed with ethanol: ethyl acetate
(1:1) solution. Finally, the pellet was rendered soluble in 500µL of
1 M NaOH, and the absorbance was read at 370 nm and reported
to the protein concentration of each sample.
Western Blot
The protein levels of MMPs and TIMP-1 were quantified
by Western blotting using the protein supernatants collected
as described above in the “Cell lysate preparation” section
incubated with primary rabbit polyclonal antibodies anti-MMP-
2 and anti-MMP-9 (dilution 1:250; Santa Cruz Biotechnology,
Santa Cruz, CA, United States). Proteins were separated
(40 µg/well) was done by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS/PAGE, 10% acrylamide) under reducing
conditions and transferred onto 0.4 µm poly(vinylidene
difluoride) membrane (Millipore) in a wet transfer system (Bio-
Rad, Hercules, CA, United States). The next steps (membrane
blocking, incubation antibodies and with chromogen solution)
were performed using the WesternBreeze Chromogenic kit
(Invitrogen) and the membranes were processed according to
manufacturer’s instructions. The obtained bands were visualized
with the Chemidoc MP system (Bio-Rad, Hercules, CA,
United States) and quantified using ImageLab software (Bio-Rad,
Hercules, CA, United States). Each sample tested was normalized
to the expression corresponding to β-actin band used as a control
of protein loading.
Gelatin Zymography
The enzymatic activities of MMP-2 and MMP-9 gelatinases
were measured following the method previously described (Stan
et al., 2015). Briefly, the samples corresponding to 50 µg of
protein (prepared in non-reducing conditions and not thermally
denaturated prior to their loading on gel) were separated on
7.5% SDS-PAGE containing 0.2% gelatin. Further, the gels were
washed two times with distilled water and incubated two times
for 15 min with renaturing buffer (50 mM Tris HCl, pH 7.6, 2.5%
Triton X-100), again washed with water and incubated overnight
at 37◦C under mild shacking with activation buffer (50 mM Tris
HCl, pH 7.6, 10 mM CaCl2, 50 mM NaCl, 0.05% Brij 35). Next,
gels were stained with Coomassie Brilliant Blue G-250, destained
with 20% ethanol – 10% acetic acid and imaged at the Chemidoc
MP system. The white bands on the blue gel, corresponding to
MMPs activity, were quantified with GELQUANT.NET software.
Histopathology
Tissue sections were fixed in 10% neutral buffered formalin
and embedded in paraffin. Paraffin sections were stained with
hematoxylin–eosin (H&E) or Fouchet van Gieson according
to the protocol provided with the Bio-Optica staining kits.
Sections were examined using an Olympus BX43 microscope and
photographed using a digital camera (Olympus XC30).
Fibrosis was graded and adapted to the method of Gui et al.
(2006): grade 0 – normal; grade 1 – fibrosis present (collagen
fiber present as small septa); grade 2 – mild fibrosis (collagen
fiber extended as septa from portal tract to central vein forming
incomplete septa); grade 3 – moderate fibrosis (collagen fibers
formed thin complete septa); and grade 4 – severe fibrosis
(collagen fibers formed thick septa).
Each sample was observed at 20× magnification. The degree
of liver damage was expressed as the mean of 10 fields of view on
each slide.
Immunohistochemistry
The primary antibodies used were rabbit polyclonal TGF-
β1, rabbit polyclonal Smad 2/3, mouse monoclonal α-SMA,
rabbit polyclonal Anti-Col-I, rabbit polyclonal NF-κB p65 and
mouse monoclonal Anti-MMP-1 antibodies. Briefly, the sections
from representative paraffin-embedding tissue samples were
deparaffinized, rehydrated, and incubated with the primary
antibody (1:100 dilution) overnight at 4◦C. Detection was
performed using a polymer detection system (Novolink max
Polymer detection system, Novocastra Leica Biosystems) and
DAB (3,30-diaminobenzidine, Novocastra Leica Biosystems)
as chromogenic substrate. Hematoxylin staining was applied
before dehydration and mounting. Negative controls included
substitution of the first antibody with normal rabbit or mouse
serum. A section of the model group was used as positive control.
Images were acquired by light microscopy (Olympus BX43,
Hamburg, Germany).
The NF-κB p65 cytoplamatic and nuclear staining was
assessed on ten separate high-power fields (200×) were randomly
chosen for each section, and five mice of each group were
examined. The percentage of hepatocytes with only nuclear NF-
κB p65 staining out of the total number of hepatocytes in each
group taken at 200×magnification was calculated.
Transmission Electron Microscopy (TEM)
Liver samples were prefixed in 2.7% glutaraldehyde solution in
0.1 M phosphate buffer, washed in 0.15 M phosphate buffer (pH
7.2), post-fixed in 2% osmic acid solution in 0.15 M phosphate
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buffer, dehydrated in acetone and then embedded in the epoxy
embedding resin Epon 812. Ultrathin sections were double
contrasted with solutions of uranyl acetate and lead citrate and
were analyzed with TEM Tecnai 12 Biotwin electron microscope.
Quantitative Real-Time PCR Analysis
Gene expression of Col I, TIMP-1, MMP-1, MMP-2, and MMP-9
were determined using real-time quantitative polymerase chain
reaction (qPCR).
Liver samples were collected from the mice in RNA later
solution (Thermo Scientific). Total RNA was isolated using
SV Total RNA Isolation kit (Promega) according to the
manufacturer’s protocol. The quantity and quality of purified
RNA was assessed using a NanoDrop 8000 spectrophotometer
(Thermo Scientific), and was afterwards reverse transcribed to
corresponding cDNA, using First Strand cDNA Synthesis Kit
(Thermo Scientific). Conditions for the reverse transcriptase
reaction were: 25◦C for 5 min, 37◦C for 60 min and 70◦C
for 5 min. Real-time PCR was performed using Maxima
SYBR Green/ROX qPCR Master Mix (Life Technologies) with
Mx3000PTM real-time PCR system. All samples were run in
triplicate.
The primers used for NF-κB 50, NF-κB 65, TNF-α, IL-6, TGF-
β1, α-SMA, Smad-2, -3, and -7, Col I, TIMP-1, MMP-1, -2, -9
mRNA detection are presented in Table 1. The mRNA levels
of target genes were normalized to the levels of glyceraldehyde
3-phosphate dehydrogenase (GAPDH), which was used as
reference gene and was assessed under the same experimental
protocol. Relative expression changes were determined using the
211C(T) method (Livak and Schmittgen, 2001).
Statistical Analysis
Data were statistically processed using GraphPad Prism 3.03
software (GraphPad Software, Inc., La Jolla, CA, United States),
and one-way analysis of variance, followed by a Bonferroni test.
p < 0.05 was considered to indicate a statistically significant
difference.
RESULTS
Phase-Solubility Analysis
Phase-solubility profiles were determined in order to characterize
the effect of cyclodextrins on silymarin solubility. Figure 2 shows
the solubility profiles of silymarin in the presence of HPBCD
and RAMEB. Both cyclodextrin derivatives were able to improve
the water solubility of silymarin in a cyclodextrin concentration
dependent manner. Solubility enhancement was calculated using
S0 and the highest silymarin concentration solubilized. According
to this parameter, RAMEB and HPBCD have similar abilities
to improve silymarin solubility in water. Contrary, sylimarin –
cyclodextrin physical mixture has been shown to have much
lower solubility than complexes (Supplementary Figures S1, S2).
Randomly methylated complexes had slightly higher
stability constant value with silymarin than HPBCD, and
their complexation efficiency (CE) values showed a similar
relationship (Table 2). CE values demonstrated that in solution,
only a small proportion of cyclodextrin molecules forms water
soluble complexes with silymarin. It means that only about one
out of three cyclodextrin molecules form a silymarin complex. As
a consequence, we used an excess amount of cyclodextrins in our
further experiments in order to guarantee the perfect dissolution
of silymarin in water and to avoid precipitation under dilution.
SEM Analysis
The morphology of raw silymarin, silymarin-cyclodextrin
complexes and silymarin-cyclodextrin physical mixtures were
examined by SEM (Figure 3). Raw silymarin showed various
block shape with wide particle size distribution. HPBCD
particles exhibited spherical shape (Figure 3A), while images
of RAMEB (Figure 3B) showed, that most of the spherical
particles were broken. The images of physical mixtures clearly
show, that the small particles of silymarin are attached
on the surface of cyclodextrin particles and together form
aggregates (Figures 3C,D). Silymarin-HPBCD or RAMEB
complexes show totally different morphology (Figures 3E,F).
TABLE 1 | Primer sequences for RT-PCR.
Target Sense Antisense
NF-κB 50 5′-AGGAAGAAAATGGCGGAGTT-3′ 5′-GCATAAGCTTCTGGCGTTTC-3′
NF-κB 65 5′-CTTGGCAACAGCACAGACC-3′ 5′-GAGAAGTCCATGTCCGCAAT-3′
TNF-α 5′CTGTAGCCCACGTCGTAGC3′ 5′ TTGAGATCCATGCCGTTG 3′
IL-6 5′AAA GAG TTG TGC AAT GGC AAT TCT 3′ 5′ AAG TGC ATC ATC GTT GTT CAT ACA 3′
TGF-β1 5′-TTTGGAGCCTGGACACACAGTACA-3′ 5′-TGTGTTGGTTGTAGAGGGCAAGGA-3′
α-SMA 5′-CCGACCGAATGCAGAAG GA-3′ 5′-ACAGAGTATTTGCGCTCCGAA-3′
Smad 2 5′-GTTCCTGCCTTTGCTGAGAC-3′ 5′-TCTCTTTGCCAGGAATGCTT-3′
Smad 3 5′-TGCTGGTGACTGGATAGCAG-3′ 5′-CTCCTTGGAAGGTGCTGAAG-3′
Smad 7 5′-GCTCACGCACTCGGTGCTCA-3′ 5′-CCAGGCTCCAGAAGAAGTTG-3′
Col I 5′CAGCCGCTTCACCTACAGC 3′ 5′ TTTTGTATTCAATCACTGTCTTGCC 3′
TIMP-1 5′GGTGTGCACAGTGTTTCCCTGTTT 3′ 5′TCCGTCCACAAACAGTGAGTGTCA 3′
MMP-1 5′-GCAGCGTCAAGTTTAACTGGAA-3′ 5′-AACTACATTTAGGGGAGAGGTGT-3′
MMP-2 5′CAG GGA ATG AGT ACT GGG TCT ATT 3′ 5′ ACT CCA GTT AAA GGC AGC ATC TAC 3′
MMP-9 5′GGACCCGAAGCGGACATTG 3′ 5′ CGTCGTCGAAATGGGCATCT 3′
GAPDH 5′-CGACTTCAACAGCAACTCCCACTCTTCC-3′ 5′-TGGGTGGTCCAGGGTTTCTTACTCCTT-3′
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A B
FIGURE 2 | Phase-solubility diagrams of Sy-HPBCD (A) and Sy-RAMEB (B) complexes.
TABLE 2 | Complexation efficiency (CE), stability constant of 1:1 complex of
silymarin formed with HPBCD and RAMEB (K1:1) and improvement of dissolution
calculated from the phase-solubility curves of silymarin complexed with HPBCD
and RAMEB.
CE K1:1 S0 (mM) Sy solubility enhancement
HPBCD 0.42 890 0.467 27
RAMEB 0.49 1060 0.467 29
After the complexation process and grinding the original
cyclodextrin and silymarin particles cannot be identified, but
aggregates containing smaller particles reveal the interaction
between silymarin and cyclodextrins. The formed new structure
contributes to the higher solubility and improved bioavailability
of silymarin.
Sy-HPBCD and Sy-RAMEB Complexes
Reduce Oxidative Damage and Increase
Antioxidant Enzymes Activities
The oxidative stress induced by CCl4 in the liver (Table 3)
was shown by the increased levels of MDA, carbonyl groups
and AOPP, which were, respectively, 2.7, 1.4, and 2.1 times,
significantly higher compared to control group. In addition, a
reduction by 50% in GSH content confirmed the CCl4-induced
toxicity in hepatic cells. A period of 2 weeks left after the CCl4
administration as a spontaneous reversion of hepatic damage
did not succeed to shift the values of MDA, GSH, and AOPP
near to those of control group, although the levels were not
as significantly changed as for the CCl4-treated mice. Only the
content of carbonyl groups was almost similar with that of
control. Regarding the benefic effect of silymarin against the
hepatic toxicity induced by CCl4, the Sy-HPBCD formulation
showed the best ability to inhibit the negative action of CCl4,
being the protein contents, the lipid oxidation products and GSH
levels similar to control mice. In contrast, the other two forms
of silymarin were not as effective as Sy-HPBCD in alleviating
the hepatic oxidative stress: an increase with 60 and 10% of
MDA level and a decrease by 25 and 14% of GSH concentration
compared to control were observed for CCl4/Sy and CCl4/Sy-
RAMEB groups, respectively.
FIGURE 3 | Scanning electron microscopy (SEM) images of HPBCD (A),
RAMEB (B), silymarin-HPBCD physical mixture (C), silymarin-RAMEB physical
mixture (D), silymarin-HPBCD complex (E), silymarin-RAMEB complex (F),
free silymarin (G).
Sy-HPBCD and Sy-RAMEB Complexes
Alleviate CCl4-Induced Structural
Changes in Liver
Liver fibrosis was evaluated in mice by two histological
methods, H&E and Fouchet van Gieson’s trichrome stain,
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TABLE 3 | The values of MDA, GSH, carbonyl groups, and AOPP concentrations after the treatment with CCl4 and various forms of silymarin
Animal group Control CCl4 CCl4 control CCl4/Sy-RAMEB CCl4/Sy-HPBCD CCl4/Sy
MDA (nmoles/mg protein) 0.036 ± 0.012 0.099 ± 0.022 ∗∗∗ 0.065 ± 0.025# 0.039 ± 0.021### 0.036 ± 0.014### 0.057 ± 0.015##
GSH (nmoles/mg protein) 1.59 ± 0.46 0.81 ± 0.25 ∗∗ 1.13 ± 0.19## 1.37 ± 0.34## 1.67 ± 0.49# 1.20 ± 0.26#
Carbonyl groups (nmoles/mg protein) 9.55 ± 0.59 13.10 ± 0.90 ∗∗∗ 9.70 ± 1.68### 9.4 ± 0.99### 9.46 ± 1.83### 10.33 ± 0.72###
AOPP (nmoles/mg protein) 55.88 ± 34.3 119.1 ± 25.0 ∗∗ 76.80 ± 57.8# 61.42 ± 39.3## 57.54 ± 26.6### 64.91 ± 19##
both assays showing the same pattern (Figure 4). The
histological analysis of the livers harvested from control mice
indicated a normal liver lobular architecture with central
vein and radiating hepatic cords, without any proliferation
of connective tissue (Figure 4A-a). Liver specimens from
CCl4 group showed severe changes in morphology, including
necrosis, obvious collagen deposition, formation of pseudo-
lobules, and infiltration of inflammatory cells in liver interstitial
areas. Hepatocytes with macro- or micro-vesicular steatosis
and congestion of sinusoids were also observed (Figure 4A-b).
However, an important degree of liver fibrogenesis and
formation of pseudo-lobules, accompanied with inflammatory
cell infiltration were still pronounced after 2 weeks of
recovery (CCl4 control group), compared with CCl4 group.
The lesions in free silymarin-treated mice were present to
a lesser degree than those found in the CCl4-treated group,
but significantly small hepatic fibrosis areas and inflammatory
infiltrations in the periportal areas were still evident. In
mice treated with Sy-HPBCD or Sy-RAMEB, the livers
showed maintained histo-architecture, almost similar to control
(Figures 4A-d,e).
The livers from control mice stained with Fouchet van
Gieson’s trichrome showed traces of collagen only in the vascular
walls (Figure 4B-a). As expected, repeated administration of
CCl4 for 7 weeks caused overt bridging fibrosis in the liver
(Figure 4B-b). Liver sections from the CCl4 group were
characterized by tissue architecture disruption, fibers extension,
large fibrous septa formation, pseudo-lobe separation, and fibers
accumulation. The extent of fibrotic changes was even still
pronounced in the CCl4 control group (p < 0.001) compared
to control (Figure 4B-c). Treatment with Sy-HPBCD or Sy-
RAMEB has significantly reduced the score of liver fibrosis,
compared to CCl4 group (p < 0.001). The degree of liver fibrosis
and thickness of fibrous septa were significantly decreased in
Sy-HPBCD group compared to Sy-RAMEB one (p < 0.05)
(Figures 4B-d,e), whereas free silymarin group exhibited almost
similar fibrosis score with that treated with RAMEB inclusion
complexes (Figure 4B-f).
Sy-HPBCD and Sy-RAMEB Complexes
Down-Regulates NF-κB Signaling and
Inflammatory Cytokines
Significant increase in NF-κB p50, NF-κB p65, TNF-α and IL-6
mRNA expressions were detected in CCl4-induced liver fibrosis
in mice, compared to control (Figures 5A,D–F). Fourteen days
of daily Sy-HPBCD or Sy-RAMEB oral administration induces
significant down-regulation of all genes compared to CCl4 group
(p < 0.001). The anti-inflammatory activity of Sy-HPBCD has
been more highlighted.
Therefore we tracked activation of NF-κB p65 in livers by
immunohistochemistry analysis (Figure 5B). In CCl4 and CCl4
control groups the p65 protein concentrated in the nucleus
(Figure 5C; p< 0.001), whereas in silymarin-cyclodextrin treated
groups p65, the expression decreased significant and localized
nearly entirely to the cytosol.
Sy-HPBCD and Sy-RAMEB Complexes
Treatment Inhibits Activation and
Proliferation of Hepatic Stellate Cells
(HSCs)
The expression of α-SMA is a characteristic feature of activated
HSCs and is considered one of the important markers of
hepatic fibrosis. The RT-PCR analysis showed significantly higher
α-SMA gene expression level for CCl4 group (p < 0.001). Both
of Sy-HPBCD and Sy-RAMEB groups presented significantly
decreased levels of gene expression, by about 9.91- and 5.24-folds,
lower compared to CCl4 group (p< 0.001). For both of silymarin-
cyclodextrin complexes the decrease was statistically significant
compared to free Sy group (Figure 6A).
In the control livers, α-SMA-immunopositive cells were
absent. For CCl4 group, intensely stained α-SMA-positive HSCs
associated with bridging fibrotic septa were present (Figure 6B).
We found the same pattern for the spontaneous reversal of
fibrosis group (CCl4 control group). However, α-SMA-positive
cells could be found nearness of fibrotic lesions in free Sy group,
while mice treated with Sy-HPBCD or Sy-RAMEB had staining
pattern almost similar to control animals.
Sy-HPBCD and Sy-RAMEB Complexes
Down-Regulate TGF-β1/Smad Signaling
Pathway
Transforming growth factor-β1 has been long considered a key
mediator in the pathogenesis of liver fibrosis, being a major pro-
fibrotic cytokine that leads to the activation of HSCs to secrete
compounds of ECM (Novo et al., 2014). Therefore, we examined
if Sy-HPBCD and Sy-RAMEB are able to inhibit the TGF-β1
expression in mice with CCl4-induced hepatotoxicity.
CCl4-induced liver fibrosis was associated with an important
up-regulation of TGF-β1 gene expression (p< 0.001). Compared
to CCl4 group, the TGF-β1 mRNA levels for Sy-HPBCD or Sy-
RAMEB groups were significantly reduced by about 72.02, and
64.2%, respectively, whereas in the CCl4 control group its levels
were found significantly higher compared to all flavonoid co-
treated groups (p < 0.001) (Figure 7A). The protective response
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FIGURE 4 | Effect induced by Sy-HPBCD and Sy-RAMEB complexes on the histological changes in liver of CCl4-treated mice. (A) H&E. (a) Control group: normal
lobular architecture and cell structure; (b) CCl4-treated group: extensive hepatocellular damage with the presence of inflammatory cell infiltration, steatosis and
necrosis, pseudo-lobular formation with collagen deposition; (c) CCl4-control group: the recovery was still weak and aspect almost similar to CCl4-treated group; (d)
CCl4 and Sy-RAMEB co-treated group: mild inflammation, minimal hepatocellular necrosis and less extended fibrotic septa; (e) CCl4 and Sy-HPBCD co-treated
group: histological aspect closest to the control with minimal inflammatory cells; (f) CCl4 and free Sy co-treated group: minimal fibrotic changes are present. ∗Fibrotic
septa and collagen deposition; arrow – inflammatory cell infiltration; scale bar – 50 µm. (B) Fouchet van Gieson trichrome. (a) Control group: no significant collagen
deposition; (b) CCl4-treated group: substantial collagen deposition in the periportal and pericellular areas, large fibrous septa formation, pseudo-lobe separation; (c)
CCl4-control group: the recovery was still weak and aspect almost similar with CCl4-treated group; (d) CCl4 and Sy-RAMEB co-treated group: less collagen
deposition was observed than that in mice treated with CCl4 alone; (e) CCl4 and Sy-HPBCD co-treated group: histological aspect closest to the control; (f) CCl4 and
free Sy co-treated group: fibrotic changes are still present; arrow- fibrotic septa and collagen deposition; scale bar – 50 µm. (C) Histogram showing the percentage
area of Fouchet van Gieson staining of collagen. ∗p < 0.05 compared to control; ∗∗∗p < 0.001 compared to control; ###p < 0.001 compared to CCl4 group;
++p < 0.01 compared to CCl4 control group; +++p < 0.001 compared to CCl4 control group; ˆp < 0.05 compared to CCl4/Sy group.
to free Sy co-treatment was lower by about 0.48-fold, respectively,
0.15-fold compared to Sy-HPBCD and Sy-RAMEB groups.
Immunohistochemical expression of TGF-β1 in the control
group was not detectable (Figure 7B-a). The CCl4 administration
significantly induced TGF-β1 immunoreactivity within the
fibrotic septa in non-parenchymal cells (Figure 7B-b). Similarly,
Kupffer cells strongly expressing TGF-β1 were infiltrated in
necrotic area around the central vein and fibrotic septa in samples
of CCl4 control group. Free silymarin treatment significantly
reduced hepatic TGF-β1 expression (Figure 7B-f), which was
completely withdrawn by 50 mg/kg Sy-HPBCD or 50 mg/kg
Sy-RAMEB administration for 2 weeks (Figures 7B-d,e).
The signaling from TGF-β1 receptors to the nucleus occurs by
phosphorylation of several cytoplasmic proteins belonging to the
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FIGURE 5 | Effects of Sy-HPBCD and Sy-RAMEB complexes on nuclear translocation of NF-kB in hepatocytes and inflammatory cytokines down-regulation in liver
fibrosis. mRNA expression of NF-κB p65 (A), NF-κB p50 (D), TNF-α (E) and IL-6 (F); Immunohistochemical staining of NF-κB p65 (B); arrow – hepatocytes with only
nuclear NF-κB p50 staining; arrowhead – hepatocytes with only cytoplasmic NF-κB p50 staining. The percentage of hepatocytes with only nuclear NF-kB p65
staining out of the total number of hepatocytes was calculated (C). Data are expressed as the arithmetic mean ± standard deviation (SD) of five mice per group;
∗∗∗p < 0.001 compared to control; ###p < 0.001 compared to CCl4 group; ##p < 0.01 compared to CCl4 group; +++p < 0.001 compared to CCl4 control group;
++p < 0.01 compared to CCl4 control group; ˆˆp < 0.01 compared to CCl4/Sy group; ˆˆˆp < 0.001 compared to CCl4/Sy group. +p < 0.05 compared to CCl4
group; ∗p < 0.05 compared to control.
Smad family (Verrecchia and Mauviel, 2002). TGF-β1 is known
to exert its fibrogenic effect through phosphorylation of Smad
2/3. Furthermore, Smad 7 is an inhibitory Smad that negatively
regulates Smad 2/3 activation and functions by targeting the
TGF-β1 receptor (Zhang et al., 2014).
As shown in Figures 7C–E, Smad 2, -3, and -7 mRNA
levels were significantly up-regulated after 7 weeks of CCl4
administration (p < 0.001). Two weeks of Sy-HPBCD or
Sy-RAMEB oral administration led to a significant decrease
of Smad 2 mRNA levels, by 75.7%, respectively, 66.21%,
whereas Smad 3 mRNA expression down-regulated by 82.65
and 75.91%, respectively, compared with CCl4 group. Otherwise,
our results showed significant up-regulation of Smad 7 mRNA
expression, by 79.71 and 66.49% for Sy-HPBCD and Sy-
RAMEB, respectively, in comparison with CCl4 group. Both
Smad 2 and Smad 3 gene expressions were significantly down-
regulated in Sy-HPBCD group compared to free Sy group
(p < 0.001). Also, the Smad 7 one was significantly up-regulated
in both Sy-HPBCD and Sy-RAMEB groups compared to free
Sy group (p < 0.001). After 2 weeks of de novo recovery
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FIGURE 6 | The mRNA expression and specific tissue distribution of α-SMA. (A) RT-PCR analysis of α-SMA gene level. ∗∗∗p < 0.001 compared to control;
###p < 0.001 compared to CCl4 group; +++p < 0.001 compared to CCl4 control group; ˆˆp < 0.01 compared to CCl4/Sy group; ˆˆˆp < 0.001 compared with
CCl4/Sy group. (B) Immunohistochemical expression of α-SMA in experimental livers. (a) Control group, (b) CCl4-treated group, (c) CCl4-control group, (d) CCl4
and Sy-RAMEB co-treated group, (e) CCl4 and Sy-HPBCD co-treated group, (f) CCl4 and free Sy co-treated group.
(CCl4 control group), the levels of Smad 2, -3 and -7 proteins
were lower, compared to all three flavonoid co-treated groups.
Immunohistochemical expression of Smad 2/3 showed the same
pattern (Figure 7F).
Sy-HPBCD and Sy-RAMEB Complexes
Down-Regulate Col 1 and Decrease
Deposition of Collagen in Hepatic Tissue
CCl4-induced liver fibrosis was associated with a marked up-
regulation of Col 1 gene expression (p < 0.001). Compared
with CCl4 group, the Col 1 mRNA levels for Sy-HPBCD or
Sy-RAMEB groups were significantly reduced by about 6.26%,
respectively, 3.89% compared to control, whereas in the CCl4
control group its level was found significantly higher compared
to all flavonoid co-treated groups (p < 0.001) (Figure 8A). The
protective response to free Sy co-treatment was lower by about
2.77-fold, respectively, 1.72-fold compared to Sy-HPBCD and
Sy-RAMEB groups (Figure 8A).
Immunohistochemical expression of Col-1 follows the same
pattern (Figure 8B).
The collagen deposition was confirmed by electron
microscopy, as shown in Figure 8C. Electron microscopy
micrographs of fibrotic group (Figure 8C-b) highlights dense
bundle of collagen fibers proliferates in the parenchima, space
of Disse and between swollen profiles of a sinusoid endothelial
cell, and maintained in self recovery group (Figure 8C-c). The
ultrastructure of livers were alleviates on Sy-HPBCD, Sy-RAMEB
and Sy-treated livers (Figures 8C-d–f).
Sy-HPBCD and Sy-RAMEB Complexes
Modulate ECM by TIMP-1/MMPs
Balance
TIMP-1 is an endogenous inhibitor of matrix metalloproteinase
(MMP) degradation of ECM. To investigate the inhibitory effects
of Sy-HPBCD and Sy-RAMEB on ECM in the livers of mice
with CCl4-induced hepatotoxicity, the mRNA levels of TIMP-
1 and MMP-1, 2, and 9 were measured by RT-PCR analysis
(Figure 9A). Our data showed that the expression levels of these
genes were significantly increased (p < 0.001) in CCl4 group
compared to control. The treatment with Sy-HPBCD or Sy-
RAMEB significantly succeeded to down-regulate the mRNA
levels of MMP-2, MMP-9, and TIMP-1 compared to those
obtained for CCl4 and CCl4 control groups (p < 0.001). By
contrast, the mRNA level of MMP-1 was significantly higher for
Sy-HPBCD and Sy-RAMEB treated groups compared to CCl4
and CCl4 control groups (p < 0.001). In Sy-HPBCD group,
the mRNA expressions of TIMP-1, MMP-2, and MMP-9 were
lower by about 2.9-, 0.46-, and 1.77-fold, respectively, compared
to free silymarin group; while gene expression of MMP-1 was
significantly up-regulated compared to the flavonoid silymarin
group (p < 0.001). Similar, for Sy-RAMEB group, the decreases
of TIMP-1, MMP-2, and MMP-9 mRNA expressions were by
about 2.23-, 0.7-, and 1.39-fold, respectively, compared to free
silymarin group. Regarding the expression of these proteins, the
immunohistochemical analysis of MMP-1 and Western Blots
of MMP-2, MMP-9, and TIMP-1 revealed the same pattern as
obtained for mRNA expression for each of them (Figure 9B). The
treatment with Sy-HPBCD or Sy-RAMEB was able to diminish
the protein levels of MMP-2 and MMP-9 recorded after the
administration of CCl4. In addition, the activity of these two
enzymes was elevated by 4.2 times in the livers of CCl4-treated
mice and further decreased near to the control levels after the
administration of Sy-HPBCD and Sy-RAMEB (Figure 9C).
DISCUSSION
Silymarin, a flavonolignan complex extracted from the seeds
of S. marianum (milk thistle), has been traditionally used
from ancient times because of its excellent hepatoprotective
activity against to a large variety of liver disorders, including
acute and chronic viral hepatitis, toxin/drug-induced hepatitis,
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FIGURE 7 | Effects of Sy-HPBCD and Sy-RAMEB complexes on TGF-β1/Smad signaling pathway. (A) RT-PCR analysis of TGF-β1 gene level. ∗∗∗p < 0.001
compared to control; ###p < 0.001 compared to CCl4 group; +++p < 0.001 compared to CCl4 control group; ˆp < 0.05 compared to CCl4/Sy group; ˆˆˆp < 0.001
compared to CCl4/Sy group. (B) Immunohistochemical expression of TGF-β1 in experimental livers. (a) Control group, (b) CCl4-treated group, (c) CCl4-control
group, (d) CCl4 and Sy-RAMEB co-treated group, (e) CCl4 and Sy-HPBCD co-treated group, (f) CCl4 and free Sy co-treated group; RT-PCR analysis of Smad 2
(C), Smad 3 (D), and Smad 7 (E) gene levels. ∗∗∗p < 0.001 compared to control; #p < 0.05 compared to CCl4 group; ##p < 0.01 compared to CCl4 group;
###p < 0.001 compared to CCl4 group; +++p < 0.001 compared to CCl4 control group; ˆˆp < 0.01 compared to CCl4/Sy group; ˆˆˆp < 0.001 compared to CCl4/Sy
group. (F) Immunohistochemical expression of Smad 2/3 in experimental livers. (a) Control group, (b) CCl4-treated group, (c) CCl4-control group, (d) CCl4 and
Sy-RAMEB co-treated group, (e) CCl4 and Sy-HPBCD co-treated group, (f) CCl4 and free Sy co-treated group.
alcoholic liver diseases and cirrhosis (Kshirsagar et al., 2009). The
preclinical results showed that anti-fibrotic properties are based
on HSC cell cycle arrest (Ezhilarasan et al., 2017), apoptosis of
the activated HSCs (Tsai et al., 2008), or free radicals scavenging
properties (Tzeng et al., 2012), leading to enhanced parenchymal
regeneration. Due to a very poor oral bioavailability, and water
solubility, silymarin is administrated in a high dose to achieve
therapeutic plasma levels. Particularly, Clichici et al. (2016)
demonstrated that a significant protection for liver fibrosis
progression fibrosis development into the liver could be achieved
by using at least 200 mg/kg Sylimarin. However, concerns about
the administration of high doses of silymarin remained, while
some results showed that it has a toxic dose of >1.44 g per
week (Wu et al., 2011). Therefore, a number of approaches have
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FIGURE 8 | Effects of Sy-HPBCD and Sy-RAMEB complexes on collagen over-production. (A) RT-PCR analysis of Col 1 gene level. ∗∗∗p < 0.001 compared to
control; ###p < 0.001 compared to CCl4 group; +++p < 0.001 compared to CCl4 control group; ˆp < 0.05 compared to CCl4/Sy group; ˆˆˆp < 0.001 compared to
CCl4/Sy group. (B) Immunohistochemical expression of Col 1 in experimental livers. (a) Control group, (b) CCl4-treated group, (c) CCl4-control group, (d) CCl4 and
Sy-RAMEB co-treated group, (e) CCl4 and Sy-HPBCD co-treated group, (f) CCl4 and free Sy co-treated group. (C) Collagen deposition in experimental livers by
electron microscopy. (a) Control group, (b) CCl4-treated group, (c) CCl4-control group, (d) CCl4 and Sy-RAMEB co-treated group, (e) CCl4 and Sy-HPBCD
co-treated group, (f) CCl4 and free Sy co-treated group; Collagen fibers (arrow); N, nucleus.
been used for the development of novel drug delivery system
in order to increase its solubility and thereby its bioavailability
(Hermenean et al., 2016), which comprise as well β-cyclodextrin
(β-CD) complexation (Arcari et al., 1992). Meanwhile, it has
been shown that water solubility of the native β-CD can
be increased, i.e., by performing a substitution of hydroxyl
groups like hydroxypropyl-β-cyclodextrin (HPBCD), where the
solubility in water raises from 18.5 mg/ml to >600 mg/ml
(Loftsson et al., 2005a,b). Other lipophilic cyclodextrin derivates,
as randomly methylated β-cyclodextrin (RAMEB), have shown
better aqueous solubility (>500 mg/ml) than native β-CD
(Loftsson et al., 2005a,b). In this respect therefore, we aimed
to develop silymarin/β-cyclodextrin derivates complexes (Sy-
HPBCD/RAMEB) with increased solubility and suitable oral
bioavailability properties, in order to maximize the anti-
fibrotic effect of silymarin in fibrotic livers at a lower dose
of 50 mg/kg. We have to note, that we selected for in vivo
testing only the silymarin/cyclodextrin complexes. This was
based on the physical and physicochemical characterization
of the complexes and physical mixtures, these data supported
the use of technologically-advanced complexes. We found that
silymarin had lower solubility in the physical mixtures than in
the cyclodextrin complexes and the low solubility can be limiting
factor of absorption (Supplementary Figures S1, S2). However,
for complete characterization of absorption, distribution and
pharmacokinetics, in vivo examinations would be needed and
thus the interpretation of the in vitro tests of physical mixtures
remains limited.
The hepatic toxicity induced by CCl4 is characterized by the
induction of oxidative stress (Hermenean et al., 2015), as it
was confirmed also in our study by the modified biomarkers
measured, such as decreased GSH level, increased carbonyl
Frontiers in Pharmacology | www.frontiersin.org 13 August 2018 | Volume 9 | Article 883
fphar-09-00883 August 9, 2018 Time: 19:1 # 14
Gharbia et al. Silymarin/β-Cyclodextrin’s Enhanced Anti-liver Fibrosis Effect
FIGURE 9 | Effects of Sy-HPBCD and Sy-RAMEB complexes on TIMP-1/MMPs modulation. (A) RT-PCR analysis of MMP-1, MMP-2, MMP-9, and TIMP-1 mRNA
expression levels. (B) Immunohistochemical expression of MMP-1 and Western Blot analysis of MMP-2, MMP-9, and TIMP-1 protein expression levels.
(C) Zymography analysis of MMP-2 and MMP-9 enzyme activity levels. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 compared to control; #p < 0.05, ##p < 0.01,
###p < 0.001 compared to CCl4 group; +p < 0.05, ++p < 0.01, +++p < 0.001 compared to CCl4 control group; ˆp < 0.05, ˆˆp < 0.01 compared to CCl4/Sy
group. ˆˆˆp < 0.01 compared to CCl4/Sy group.
groups amount and more than double levels of lipid peroxidation
and AOPPs (Table 3). Antioxidant efficiency of sylimarin and its
β-cyclodextrin formulations (Sy-HPBCD and Sy-RAMEB) was
proved by the diminished biomarkers’ levels compared to CCl4-
treated group. Particularly, levels assessed in the samples from
mice treated with CCl4/Sy-HPBCD were almost comparable
with those of control group, indicating that this HPBCD
hydroxypropyl β-CD-based formulation had the most potent
activity to alleviate the oxidative stress triggered by CCl4 on livers.
Nuclear factor kappa-light-chain enhancer of activated B cells
(NF-κB) is a key transcription factor involved in chronic liver
disease, with a particular focus on chronic inflammation and
fibrosis (Papa et al., 2009). NF-κB family consists of p50 (NF-
κB1), p52 (NF-κB2), p65 (RelA), c-Rel (Rel), and RelB members,
of which p65, RelB and cRel contain C-terminal transactivation
domains that trigger gene transcription. NF-κB p50 become
active DNA-binding proteins after cleavage of p105 precursor
and activate transcription when form heterodimers with subunits
that contain transactivation domains, especially p65 (Luedde
and Schwabe, 2011). Our results suggest that Sy-HPBCD and
Sy-RAMEB complexes exerts a crucial role in inflammation
alleviation and subsequent fibrosis resolution by down-regulation
of the major pro-inflammatory liver cytokines as TNF-α and IL-6
through NF-κB p50 and 65 regulatory genes inhibition.
Previous studies have demonstrated a positive correlation
between HSC activation and the degree of hepatic fibrosis
(Novo et al., 2014). The hepatic α-SMA expression is an
important and reliable marker of activated HSC in situ (Jarcˇuška
et al., 2010), which is recognized as being crucial in liver
fibrogenesis. Additionally, HSCs activation is the main source
of excessive ECM protein synthesis and deposition. During
liver damage, HSCs become activated and trans-differentiate
into myofibroblast-like cells, being accompanied by higher
proliferation, expression of α-SMA and overproduction of
ECM (Friedman, 2003). Our data revealed that α-SMA hepatic
expression in fibrotic mice (CCl4 group) was significantly
increased (Figure 4). This was also consistent with previous
observations in rodent models of CCl4-induced fibrosis (Amin
and Mahmoud-Ghoneim, 2009; Domitrovic´ et al., 2009; Hamza,
2010; Balta et al., 2015). Meanwhile, treatment by Sy-HPBCD
and Sy-RAMEB significantly decreased α-SMA expression level
in liver of CCl4-treated mice (Figure 4). These results suggest that
Sy-HPBCD and Sy-RAMEB could protect mouse liver against
CCl4-induced damage. Furthermore, the RT-PCR analysis
confirmed that α-SMA mRNA hepatic level was down-regulated
by Sy-HPBCD and Sy-RAMEB administration, whereas free
silymarin administration exerted a lower protection (Figure 4A).
Transforming growth factor-β1 (TGF-β1), the most potent
pro-fibrogenic cytokine, has been suggested to be an important
factor in activating and promoting the transformation of HSCs
(Mallat and Lotersztajn, 2013), and an active regulator of
the production, degradation, and deposition of ECM proteins
Frontiers in Pharmacology | www.frontiersin.org 14 August 2018 | Volume 9 | Article 883
fphar-09-00883 August 9, 2018 Time: 19:1 # 15
Gharbia et al. Silymarin/β-Cyclodextrin’s Enhanced Anti-liver Fibrosis Effect
(Iredale et al., 2013), through Smad-dependent and -independent
signaling pathways (Zhang et al., 2014). Initially, stored
as an inactivated protein, once activated, TGF-β exerts its
biological and pathological activities via Smad-dependent and
-independent signaling pathways (Zhang et al., 2014). Thus,
the TGF-β signaling pathway has become a main effective
target for the prevention and therapy of hepatic fibrosis. In the
present study, both types of silymarin-cyclodextrin formulations
significantly attenuated the level of TGF-β1, indicating their
inhibitory activity against the proliferative activity of HSCs,
which might be confirmed by less fibrosis scars, collagen down-
regulation and tissue deposition compared to fibrotic livers
(CCl4 group), even after 2 weeks of recovery (CCl4 control
group) (Figures 5A,B). Moreover, CCl4-induced liver fibrosis
was associated with an important activation of Smad 2/3
expression and a lower increase of Smad 7 one, compared
to control (Figures 5C–F). This imbalance between Smad 2/3
and Smad 7 signaling could represent also a significant event
in the pathogenesis of liver fibrosis. Also, the overexpression
of Smad 7 attenuated TGF-β/Smad signaling in liver and
protected against HSCs activation and fibrogenesis in liver
fibrotic rodent models (Bian et al., 2014). Our results showed that
both Sy-HPBCD or Sy-RAMEB treatments were able to down-
regulated the expression of Smad 2/3 and reversed the inhibitory
effect of CCl4 on Smad 7 expression. The gene expression
of Smad family through Sy-cyclodextrin complexes were more
significant modulated than non-complexed silymarin. Therefore,
we hypothesized that the decreased fibrosis level after Sy-HPBCD
and Sy-RAMEB treatment might be mediated via inhibition of
TGF-β1/Smad signaling pathway.
Hepatic fibrosis is a wound healing response to liver injury
and is characterized by extensive deposition of ECM proteins,
such as collagen types I, III, and IV, laminin as well as hyaluronic
acid, leading to a decreased capability of specific catabolism
(Iredale et al., 2013). In this study, the Col I mRNA expression in
hepatic tissue and collagen deposits were significantly increased
in CCl4-treated rats, whereas Sy-HPBCD and Sy-RAMEB
treatment markedly down-regulated Col I, highlights that both
Sy-cyclodextrin complexes can prevent collagen accumulation
caused by the chronic liver injury and alleviates the development
of liver fibrosis (Figure 6).
In the fibrotic livers, MMPs as well as their endogenous
inhibitors, tissue inhibitors of metalloproteinases (TIMPs), are
highly expressed. During fibrosis resolution induced by Sy-
HPBCD and Sy-RAMEB administration, the mRNA TIMP-
1 expression was significantly declined, tipping the overall
MMPs/TIMP balance, resulting in increased matrix degrading
activity and net degradation of scar tissue (Afratis et al.,
2018), compared with silymarin group, as we showed in
Figures 3, 7.
Matrix metalloproteinases collagenases are central to the
process of fibrotic tissue remodeling because they cleave the
native helix of fibrillar collagens and providing the gelatin
susceptible to degradation by other MMPs (Iredale et al., 2013).
This study showed that both Sy-HPBCD and Sy-RAMEB were
able to up-regulate mRNA and protein MMP-1 (interstitial
collagenase) expression and further stimulate cleavage of the
native fibrillar collagens, especially Col I, by regulating the
extracellular matrix balance via TIMP-1/MMP-1 components
(Figure 7).
Matrix metalloproteinases gelatinases, as gelatinase A (MMP-
2) are expressed by Kupffer cells and inflammatory macrophages
(Préaux et al., 1999), respectively, gelatinase B (MMP-9) by
activated stellate cells (Han et al., 2007), contribute to ECM
remodeling. They are implicated in the activation of TGF-β, that
is crucial for the differentiation of quiescent HSC into collagen I
producing myoblasts (Zbodakova et al., 2017). Our data showed
that gene expression of MMP-2 and MMP-9 remained increased
after 7 weeks of CCl4 administration, which is in agreement
with other findings (Watanabe et al., 2001; Zhou et al., 2004;
Cheung et al., 2009). We also found that Sy-complexes abrogated
CCl4-induced MMP-2/MMP-9 up-regulation. Recent studies
highlighted that inhibition of MMP-2, and MMP-9 activities or
blockade of their synthesis by other bioactive compounds, such
as: betaine (Bingül et al., 2016), morin (Perumal et al., 2017),
isoorientin (Lin et al., 2015) or helenalin (Lin et al., 2014), might
effectively prevent HSC activation and proliferation and collagen
accumulation.
Furthermore, it was shown the ability of both Sy-HPBCD and
Sy-RAMEB to re-establish the right protein level of MMPs and
TIMP-1 after the administration of CCl4, in order to regulate
the degradation and accumulation of ECM (Figure 7B). The
complexation of sylimarin with β-CD clearly contributed to the
attenuation of liver fibrosis induced experimentally in mice by
CCl4, as the free silymarin administration was not so efficient.
This approach used within this work, the measurement of mRNA,
protein and activity level of MMP-2 and MMP-9 on a long-term
treatment, together with the expression of TIMP-1, allows us
to validate the complex modulation of these molecules involved
in the pathogenesis of liver fibrosis by Sy-HPBCD and Sy-
RAMEB, in order to counteract the CCl4-induced damage. These
results are in agreement with the attenuation of oxidative stress
(Table 3), as it is known that reactive oxygen species, most
probably over generated by CCl4, can activate MMPs through the
oxidation of cysteine pro-domain or modification of amino acids
from catalytic domain. Previously it was proved that silymarin
decreased the expression of MMP-2 and MMP-9 in human
melanoma cells (Vaid et al., 2011), having beyond the protective
action of hepatocytes an anticancer potential (Agarwal et al.,
2006).
One of the major signs of the liver fibrogenesis involved free
cholesterol accumulation in HSCs and thereby stimulated the
cells to TGF β-induced activation via TLR-4 signals (Tomita et al.,
2014). Probably, enhanced antifibrotic effects of the complexes
can be attributed additionally to β-cyclodextrin’s which can exert
metabolic effects either directly through binding lipid molecules
such as cholesterol or indirectly via microbiota-dependent
generation of bioactive metabolites, translated in reduced plasma
total cholesterol levels and lower HDL cholesterol (Mistry et al.,
2017).
Taking into account that tested formulation are able to repair
the oxidative damages and to modulate the turnover of ECM
throughout the MMP/TIMP rebalance. Sy-HPBCD was found
to be the most potent anti-fibrotic complex, but both of these
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can represent valid sylimarin-containing products with increased
biodisponibility for treating liver fibrosis.
CONCLUSION
We have demonstrated that Sy-HPBCD and Sy-RAMEB
complexes decreased extracellular matrix accumulation by
inhibiting HSC activation, diminished the oxidative damage and
increased antioxidant defense system. Mechanistically, this might
occur via inhibition of the TGF-β1/Smad signal transduction,
and MMP/TIMP rebalance, by blocking the synthesis of Col I
and decreasing collagen deposition. These results suggest that the
complexation of silymarin with HPBCD or RAMEB are viable
options for the its oral delivery, of the flavonoid as a potential
therapeutic entity candidate with applications in the treatment of
liver fibrosis.
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